Vor Biopharma Inc complete an upsized $176.9 million IPO, offering 9.83 million shares at $18 each.
The stock opened at $42.02 was jumped 104.9% in early action.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.79 |
|---|---|
| 52-week range | $0.63 - $3.14 |
| 50-day moving average | $0.78 |
| 200-day moving average | $1.31 |
| Wall St. target price | $11.92 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.64 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.79 from 2024-11-22
| 1 week (2024-11-15) | -8.56% |
|---|---|
| 1 month (2024-10-25) | 8.67% |
| 3 months (2024-08-23) | -17.19% |
| 6 months (2024-05-24) | -49.20% |
| 1 year (2023-11-24) | -57.07% |
|---|---|
| 2 years (2022-11-23) | -81.84% |
| 3 years (2021-11-24) | 12.48 |
| 5 years (2019-11-21) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -39.74% |
| Return on equity TTM | -78.07% |
| Profit margin | 0% |
| Book value | $2.22 |
| Market Capitalization | $54.3 million |
TTM: trailing 12 months
We're not expecting Vor Biopharma Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Vor Biopharma Inc's shares have ranged in value from as little as $0.63 up to $3.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vor Biopharma Inc's is -0.408. This would suggest that Vor Biopharma Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vor Biopharma Inc has bucked the trend.
To put Vor Biopharma Inc's beta into context you can compare it against those of similar companies.
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.